Trouble reading this email? View it in your browser
European Federation of Pharmaceutical industries and associations
   

EFPIA Newsletter 7 November 2019

 
 
 
   

Blogs

 

“If you always do what you’ve always done, you’ll always get what you’ve always got”
07 November 2019 - Nathalie Moll

We need to work together to ensure access to treatments today and develop the medicines of the future. Read more

In a world of finite resources, we cannot afford an inefficient use of health spending
06 November 2019 - Roberta Savli

Around 10% of EU GDP is spent on healthcare; yet, as much as one-fifth is spent inefficiently, making no meaningful... Read more

 
 
 
   

Events

 

Evidence-based expertise for better policy-making
08 November 2019 (Brussels)

Expert panel on effective ways of investing in health end of mandate conference Read more

Data Protection in Health Research
19 November 2019 (Brussels)

A dialogue among policymakers, authorities, manufacturers of medicinal products and medical technologies, and other... Read more

Improving health outcomes for people with diabetes
21 November 2019 (European Parliament)

The role of data, access to innovation and integrated care Read more

Is there a future in Clinical and Pharmacovigilance Quality Management?
29 January 2020 (Leuven, Belgium)

A unique event to interact with all stakeholders from the pharma and biotech industry, investigational sites and regulators.... Read more

 
 
 
   

What we are reading

 

Orphan Medicines for Pediatric Use: A Focus on the European Union
On 05 November 2019 (Clinical Therapeutics)

This article discusses the EU Orphan Regulation, Paediatric Regulation, and the implications of the intersection of... Read more

EU Commissioner: ‘I Will Always Be a Vaccine Advocate’
On 04 November 2019 (Vaccines Today)

In an exclusive interview, Vytenis Andriukaitis, European Commissioner responsible for health, calls for harmonised... Read more

A new Alzheimer’s therapy is approved in China, delivering a surprise for the field but also...
On 04 November 2019 (STAT)

Chinese regulators have granted conditional approval to an Alzheimer’s drug that is derived from seaweed, potentially... Read more